Early Treatment of Childhood Hepatitis B Enhances Long-Term Virus Suppression
Recent research highlights the significant benefits of proactive treatment for children with chronic hepatitis B virus (HBV) infection. A long-term study conducted by scientists at National Taiwan University and its Children's Hospital has demonstrated that children who undergo high-genetic-barrier nucleos(t)ide analog therapy before their HBeAg seroconversion markedly increase their chances of achieving a functional cure, characterized by sustained suppression of HBV surface antigen (HBsAg) and undetectable HBV DNA levels.
The study involved tracking 413 patients from childhood into adulthood over approximately 10,888 person-years, revealing that HBeAg seroconversion during childhood (before 18 years of age), combined with prior high-barrier antiviral therapy and low HBsAg titers (less than 1,000 IU/mL at 18 months post-seroconversion), significantly predicted long-term viral control.
Historically, the course of chronic HBV in children was viewed as benign with minimal intervention. However, emerging evidence suggests that early treatment, especially with high-genetic-barrier nucleos(t)ide analogs before seroconversion, can lead to better clinical outcomes and reduce late complications such as liver fibrosis and hepatocellular carcinoma (HCC).
These findings are particularly relevant in the context of the World Health Organization’s goal to treat over 80% of individuals with chronic hepatitis B by 2030. While current guidelines have started to shift focus towards achieving a functional cure rather than mere viral suppression, the evidence supports a reevaluation of treatment strategies for pediatric patients.
The research underscores the importance of close follow-up and early antiviral intervention in children with chronic HBV to improve their chances of long-term virus control and potentially alter the natural history of the disease. This paradigm shift in management could have significant implications for global hepatitis B control efforts.
Source: https://medicalxpress.com/news/2025-04-childhood-hepatitis-treatment-linked-higher.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Breakthrough Treatments Developed to Prevent Life-Threatening HTLV-1 Virus Infection
Researchers have developed the world's first treatments to prevent the transmission of HTLV-1, a deadly virus affecting millions globally, using existing HIV medications in innovative ways.
Innovative Tree Map Technology Aims to Reduce Allergies in Major Australian Cities
A new visualization tool by Edith Cowan University maps allergenic trees in Australian cities, helping residents avoid pollen hotspots and reduce allergy symptoms through data-driven strategies.
Impacts of the 'One Big Beautiful Bill' on Older Adults' Healthcare
Explore how the recent healthcare legislation, 'One Big Beautiful Bill', will affect older adults' access to Medicare, Medicaid, and long-term care services in the USA.
The Role of Education and Social Factors in Rheumatic and Musculoskeletal Diseases
Emerging research emphasizes the critical role of social determinants like income and education in shaping outcomes for patients with rheumatic and musculoskeletal diseases. Findings from the EULAR 2025 congress reveal how these factors influence disease progression and mortality, highlighting the need for targeted interventions to promote health equity.